United Therapeutics Q2 rev up 12% YoY to $799 mln, Tyvaso DPI rev up 22% YoY to $315 mln.

• United Therapeutics Q2 2025 financial results record $799 million revenue. • 12% growth YoY, 12 consecutive quarters of double-digit growth. • Tyvaso DPI revenue reaches $315 million, 22% growth YoY. • No other treprostinil inhaler has been studied at higher doses. • Nebulized Tyvaso, Orenitram, and Unituxin show double-digit growth YoY. • Phase 3 TETON 2 study of Nebulized Tyvaso in idiopathic pulmonary fibrosis complete. • Board of Directors authorizes $1 billion share repurchase. • Expired on March 31, 2026.

United Therapeutics Corporation (NASDAQ: UTHR) announced record financial results for the second quarter of 2025, driven by continued double-digit year-over-year (YoY) revenue growth across its key products. The company reported total revenues of $799 million, a 12% increase from the same period in 2024, marking 12 consecutive quarters of double-digit revenue growth.

Tyvaso DPI, a best-in-class treprostinil dry powder inhaler, generated $315 million in revenue, representing a 22% YoY growth. The product's unique feature of one breath per cartridge, four times a day, with low inspiratory effort, has contributed significantly to its success. Notably, no other commercially available treprostinil dry powder inhaler has been studied at higher doses [1].

Nebulized Tyvaso, Orenitram, and Unituxin also demonstrated double-digit YoY revenue growth. The phase 3 TETON 2 study of Nebulized Tyvaso in idiopathic pulmonary fibrosis was completed, with data expected in September 2025. The company also reported the completion of enrollment for the phase 3 ADVANCE OUTCOMES study of ralinepag in pulmonary arterial hypertension, with data expected in the first half of 2026 [2].

The Board of Directors authorized a share repurchase program of up to $1 billion, set to expire on March 31, 2026. This move underscores the company's commitment to a robust and balanced capital allocation philosophy, driven by strong financial performance and the potential for upcoming clinical trial data to further enhance its product portfolio.

References:
[1] https://seekingalpha.com/news/4474082-united-therapeutics-gaap-eps-of-6_41-misses-by-0_51-revenue-of-798_6m-misses-by-5_05m
[2] https://markets.ft.com/data/announce/detail?dockey=600-202507300630BIZWIRE_USPRX____20250730_BW536774-1